CN Patent

CN118440135A — 用于治疗高钾血症的甘草次酸衍生物

Assigned to Ardelyx Inc · Expires 2024-08-06 · 2y expired

What this patent protects

本发明提供式(I)的化合物或其盐：(I)其中X、L、V、R 1 、R 2 、R 3 和R 4 如本文所定义。这些化合物是2型11‑羟基类固醇脱氢酶(11‑HSD‑2)的抑制剂，并且用于治疗高钾血症。

USPTO Abstract

本发明提供式(I)的化合物或其盐：(I)其中X、L、V、R 1 、R 2 、R 3 和R 4 如本文所定义。这些化合物是2型11‑羟基类固醇脱氢酶(11‑HSD‑2)的抑制剂，并且用于治疗高钾血症。

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: CN118440135A
Jurisdiction: CN
Classification: —
Expires: 2024-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Ardelyx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.